No Data
No Data
AstraZeneca Says Potential Breast Cancer Treatment Reduces Risk of Disease Progression by up to 38%
AstraZeneca (AZN) said Sunday that a phase 3 trial of Enhertu showed ""statistically significant and clinically meaningful improvement" in treating certain types of metastatic breast cancer over chemo
Buyback movements intensified, mainly in value stocks, and temporarily recovered to the 39,000 yen level
The Nikkei Average continues to rise. The transaction closed at 38923.03 yen (estimated turnover is 1.67 billion shares), which rose by 435.13 yen. Since the sense of caution against excessive high inflation receded in the US market the previous weekend, investor sentiment improved against the backdrop of a trend where the NY Dow rose drastically. Buying took precedence over a wide range of stocks, and the Nikkei Average rose to 39032.50 yen before trading began, and during trading hours, it recovered to the 39,000 yen level, a psychological milestone for the first time in 3 business days since 5/29. just
Reported Earlier, Daiichi Sankyo And AstraZeneca's ENHERTU Shows Progression-Free Survival To 13.2 Months In HR Positive, HER2 Low Metastatic Breast Cancer
DESTINY-Breast06 results show Daiichi Sankyo and AstraZeneca's ENHERTU is the first HER2 directed medicine and antibody drug conjugate to demonstrate clinically meaningful benefit for patients in this
The Nikkei Average rose by 468 yen, and the Dow Jones Industrial Average futures etc. are strong, so there is a sense of security
The Nikkei Average is 468 yen higher (as of 13:50). In terms of the Nikkei average contribution, First Rate <9983>, East Elec <8035>, TDK <6762>, etc. are top positive contributors, while Daiichi Sankyo <4568>, DISCO <6146>, Socionext <6526>, etc. rank high for negative contributions. In the sector, securities commodity futures, insurance, shipping, mining, and warehousing-related industries have the highest price increase rates, electric/gas, non-ferrous metals, metal products, pharmaceuticals, and transportation
AstraZeneca Reports Positive Results for Metastatic Breast Cancer Drug
AstraZeneca (AZN.L, AZN.ST) on Sunday reported positive results in the Destiny-Breast06 phase 3 trial of Enhertu on patients with metastatic breast cancer. The biopharmaceutical company is developing
Nikkei Average Contribution Ranking (advance closing) ~ The Nikkei Average continued to rise, boosted by about 110 yen for 2 brands, Fast Rite and East Elek
The number of gains and falls of the Nikkei Average constituent stocks as of closing 3 days ago was 187 stocks with price increases, 37 stocks with price drops, and 1 stock unchanged. The Nikkei Average continues to rise. The front-end transaction was closed at 38849.65 yen (estimated turnover of 860 million shares), which was 361.75 yen higher (+0.94%) compared to the previous business day. The US stock market on May 31 was mixed. The Dow average rose by $574.84 (+ 1.51%) to $38686.32, and the Nasdaq fell 2.06 points (-0.01%) to 1673
No Data